AIM: Thiazolidinediones (TZD) are a new class of oral antidiabetic drugs that have been shown to inhibit growth of same epithelial cancer cells. Although TZD were found to be ligands for peroxisome proliferator-activated receptor  (PPAR), the mechanism by which TZD exert their anticancer effect is presently unclear. In this study, we analyzed the mechanism by which TZD inhibit growth of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma.
INTRODUCTION
Pancreatic cancer is a devastating disease characterized by an increased incidence in western industrialized countries, an extremely poor median survival of 4-6 mo after diagnosis [1] , and limited therapeutic options [2] . The majority of pancreatic cancers arises from the pancreatic duct cells and is characterized by uncontrolled growth, inability to express the differentiated features of normal duct cells and progressive accumulation of multiple genetic abnormalities [3] . It has been suggested that the pharmacological induction of cellular differentiation might be an alternative to conventional tumor chemotherapy. The activation of the terminal differentiation program in genetically abnormal tumor cells is strictly associated with irreversible growth arrest [4] . In pancreatic cancer cells, retinoids, for example, induce differentiation and inhibit growth by activation of their specific nuclear receptors [5, 6] suggesting that other nuclear receptors involved in the regulation of cellular differentiation might be targets for novel therapeutic strategies of pancreatic cancer.
Thiazolidinediones (TZD) such as pioglitazone (PGZ) and rosiglitazone (RGZ) are a new class of antidiabetic drugs, which attenuate the insulin resistance associated with obesity, hypertension and impaired glucose tolerance in humans as well as in several animal models of non-insulin-dependent diabetes mellitus [7] . TZD were found to be ligands for peroxisome proliferator-activated receptor  (PPAR), a member of the nuclear receptor superfamily of liganddependent transcription factors that is predominantly expressed in adipose tissue although it is also expressed in other tissue at much lower levels [8] [9] [10] . In adipose tissue PPAR functions as a master regulator of adipogenesis and its ligand-mediated activation in fibroblasts induces adipocyte differentiation and lipid storage [11, 12] . TZD activate PPAR and promote association with 9-cis retinoic acid receptor (RXR) to form functional heterodimers, which recognize their cognate response element at the level of target genes [13, 14] . Several recent studies have indicated that TZD may have anticancer properties in a variety of different epithelial malignancies including breast, prostate and gastrointestinal cancers [15] [16] [17] . Treatment of cultured breast and colon cancer cells with TZD resulted in a reduction in growth rate and induction of apoptosis [18, 19] . Furthermore, human colorectal cancer cells implanted in nude mice were shown to grow more slowly in mice treated with TZD, with a 50% reduction of tumor volume [20] . In addition loss-of-function mutation of the PPAR gene has been found in some human colon and thyroid carcinomas [21, 22] . As a consequence, PPAR has become a molecular target for anticancer drug development, and TZD have been proposed for therapy of PPAR-expressing tumors.
Although preliminary evidence has shown that, troglitazone, the first TZD marketed for use in humans, inhibited pancreatic cell proliferation [23, 24] , the mechanism by which these drugs inhibit cell growth in these cells has not been conclusively established.
In this study we demonstrated that exposure of pancreatic cancer cells to TZD inhibited anchorage-independent growth with a PPAR-dependent differentiation-inducing mechanism. Surprisingly the ductal pro-differentiation program induced by PPAR activation was not associated with apoptosis in these cells.
MATERIALS AND METHODS

Materials
Most chemicals and supplies were purchased from Sigma Chemical Company (St. Luis, MO). Nitrocellulose and Nytran were from Schleicher and Schuell, Inc., (Keene, NH). Agarose, trypsin, all restriction endonucleases, DNAmodifying enzymes, and tissue culture media were purchased from Gibco BRL (New Brunswick, NJ). Fetal bovine serum (FBS) was from HyClone Laboratories (Logan, UT). D-threo-[dichloroacetyl-1,2-14 C]-chloramphenicol was purchased from New England Nuclear (Boston, MA). Rosiglitazone and pioglitazone were from SmithKline Beecham Pharmaceuticals (Welwyn, UK) and Takeda Chemicals (Tokyo, Japan) respectively.
Tissue sample and cell cultures
The pancreatic adenocarcinoma cell lines PANC-1, CAPAN-2, and HPAC were obtained from the American Type Culture Collection (ATCC, Rockville, MD). Cells were maintained in Dulbecco's modified Eagles medium (DMEM; GIBCO Laboratories, Grand Island, NY) containing 10% fetal bovine serum (FBS, Gibco). Culture medium was supplemented with 50 U/mL penicillin and 50 g/mL streptomycin. All experiments were performed in phenol red-free medium.
Tumor clonogenic assay
Pancreatic cancer cells were trypsinized and disaggregated through a 19-gauge needle into a single-cell suspension, as evaluated by microscopy. Cells 2×10 4 were mixed with DMEM/5% dialyzed FBS containing 0.3% agarose and TZD at the concentration indicated. Cells were then layered over a solid base of 0.5% agarose in the same medium, in 60-mm dishes. The cultures were incubated in humidified 50 mL/L CO 2 /95% air at 37 ℃. After 14 d the colonies were counted by an Omnicon 3 600 Colony Counter and photographed.
Cell cycle analysis
Cells (4×10 5 ) were exposed to TDZ for 4 d in medium supplemented with 5% dialyzed FBS. Total cells both in suspension and adherent, were collected, washed, suspended in cold PBS, and stained in trypan blue. Both blue and nonblue cells were counted. The cells were adjusted to 1×10 6 viable cells/mL and fixed in 2:1 ratio (v/v) in methanol overnight before staining with propidium iodide. Cell cycle status was analyzed with Becton Dickinson Flow Cytometer and CellFIT Cell-Cycle Analysis software.
Protein extract and Western blot
Whole-cell proteins were extracted from the different adenocarcinoma cell lines. Cells were cultured in the presence or absence of test agents and were homogenized in Laemmli buffer [25] . Nuclear proteins were isolated from treated and untreated cells based on micro preparation methods [26] . The nuclear extracts were suspended in 20 mmol/L HEPES (pH 7.9), 40 mmol/L NaCl, 1.5 MgCl 2 , 0.2 mmol/L ethylenediaminetetraacetic acid, 25% glycerol, 0.5 mmol/L dithiothreitol, and 0.2 mmol/L phenylmethylsulfonyl fluoride. Lysates were centrifuged at 20 000 g for 10 min at 4 ℃ and supernatants were frozen in liquid nitrogen and stored at -80 ℃ until use. Nuclear and whole-cell extracts (40 g protein) were fractionated in 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electro blotted onto nitrocellulose filters. Proteins were detected by incubating the filters with the following primary antibody: mouse anti-human PPAR (1:500) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), sheep anti-human carbonic anhydrase II (1:500) [27] cytokeratin 7 (1:1 500) (Novocastra Lab, Newcastle UK), p21 (1:1 000) (Santa Cruz Biotechnology, Santa Cruz, CA) and p27 (1:1 000) (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-human bcl-2, bax, and bcl-xl (1:1 000) (Transduction, Laboratories, San Diego CA) mouse anti human bax (1:1 000), and mouse anti-human bak (1:1 000) (CalBiochem, San Diego CA). Detection of the protein bands was performed using the Amersham ECL kit (Arlington Heights, IL).
RNA extraction and RT-PCR
Total RNA was extracted from cultured cells and by guanidinium-phenol-chloroform methods of Chomczynski and Sacchi [28] with minor modifications [29] . 
Transient transfection of culture cells
Cells were transfected at the density of 5×10 5 cells/60 mm dish with 2.5 g of peroxisome proliferator response element (ARE) 3 -tk-luciferase reporter plasmid (containing 3 copies of the PPRE from the adipocyte lipid-binding protein (aP2) gene ligated to a herpes simplex thymidine kinase promoter upstream of a luciferase gene) [30, 31] , and 5 g of pSV 2 CAT (vector containing SV40 early promoter and enhancer sequences that drives a chimeric chloramphenicol acetyl transferase [CAT] gene) as an internal control by calcium phosphate precipitation. Total amount of DNA transfected was normalized with a carrier DNA (pcDNA3.1; Invitrogen Corporation, Carlsbad, CA). Four hours later the cells were exposed to PBS containing 15% glycerol for 3 min. The cells were rinsed twice with PBS and fresh serum supplemented with 5% dialyzed FBS was added. Twenty four hours after transfection cells were treated with TZD. Twenty four hours later, the cells were harvested, washed twice with PBS, and lysed in 150 L of buffer containing 25 mmol/L Tris, pH 7.8, 2 mmol/L ethylenediaminetetraacetic acid, 20 mmol/L dithiothreitol, 10% glycerol, and 1% Triton X-100. Fifty microliters of cell extract were incubated with luciferase assay reagent based on the original protocol of de Wet et al [32] . The number of relative light units with a 3-s delay and 30-s incubation were measured by Sirius1 luminometer (Berthold Detection System, Pforzheim/ Germany). CAT activity was measured as described previously [33] . The conversion of chloramphenicol to its acetylated products was quantified on Ambis beta scanner (Ambis System, San Diego, CA).
Generation of the PPAR-expressing cell line
Human PPAR cDNA was cloned into pLNCX, a retroviral vector driving expression of the cloned cDNA from the cytomegalovirus promoter and conferring resistance to G418. Retrovirus plasmid was transfected into a packaging cell line, PA317, and used to transduce HPAC cells as previously described [34] . In brief, PA317 were transfected with 10 g of the cloned construct (PPAR-pLNCX) or the empty retroviral vector, using calcium phosphate precipitation followed by glycerol stock as described above. Twenty four hours after transfection the virus-containing supernatant was removed, filtered through a 45-m filter, and stored at -70 ℃. A total of 5×10 5 HPAC cells were infected with 10 6 cfu/mL virus in the presence of 6 g/mL polybrene. Twenty four hours later the cells were replated in duplicate and selected with 600 g/mL of the antibiotic G418. After selection of G418-resistant cells, the clones were expanded and screened for PPAR expression by Western blotting.
Apoptosis assay
Following the indicated treatments, apoptosis was measured by a DNA fragmentation assay (Apo-Direct) as recommended by the manufacturer (PharMingen, San Diego, CA). Briefly, cells (adherent and floating) were fixed in 1% formaldehyde in PBS overnight. After washing, 10 6 fixed cells were incubated with terminal deoxynucleotidyl transferase enzyme (TdT) and FITC-dUTP for 90 min at 37 ℃ to label DNA breaks. Cells were rinsed, incubated in RNaseA/propidium iodide in the dark for 30 min at room temperature to stain total DNA, and then analyzed by flow cytometry. Cells doublets and clumps were eliminated from the analysis by gating.
Statistical analysis
Data was expressed as mean±SD. Statistical correlation of data was checked for significance by ANOVA and paired Student's t test. The corresponding probability (P) is given.
RESULTS
TZD inhibited anchorage-independent growth of human pancreatic cancer cells with a PPAR-dependent mechanism
We initially investigated the effect of TZD on pancreatic cancer cell growth. The effect of TZD on anchorageindependent growth was assessed by cloning cancer cells in soft agarose. Treatment with both TZD at the concentration of 10 mol/L resulted in a significant inhibition of colony formation by Panc-1 and Capan-2 cell lines, whereas drug treatment was ineffective in the PPAR non-expressing HPAC cells ( Figure 1A, B) . Clofibric acid was used as a negative control. The dose dependency for the anchorageindependent growth inhibition was further characterized in Panc-1 cells. PGZ inhibited colony formation in a dosedependent manner in Panc-1 cell line ( Figure 1C) . Moreover, the size of the colonies was significantly smaller in the RGZtreated cells compared to cells treated with vehicle alone.
To confirm the role of PPAR in TDZ-induced growth arrest, we generated a PPAR-expressing HPAC cells using transducing retroviruses. Four isolated HPAC clones showed selective overexpression of PPAR protein compared to parental wild type and mock-transfected controls (Figure 2A ). Of the selected clones, number 3 (P3-HPAC) was used for further studies. In these cells, PGZ induced the activity of the ARE-7 3 -tk-luc reporter in a dose-dependent manner ( Figure 2B ) and this effect was correlated to a significant inhibition of anchorage-independent growth ( Figure 2C ).
PPAR activation by TZD alters cell cycle progression but does not induce apoptosis in pancreatic cancer cells
Preliminary experiments evaluating trypan blue exclusion and lactate dehydrogenase leakage from pancreatic cancer cells into the culture medium showed that both TZD induced growth inhibition rather than cytotoxicity, because the number of vitally stained cells was higher than 90% in all experiments at any given time point. Based on this observation, documented in the PPAR-deficient HPAC line, whereas the inhibition of cell cycle progression by TZD was restored in P3-HPAC cells. To determine whether the inhibitory effect of TZD was in part mediated by inducing apoptosis, cells were treated with RGZ or PGZ for 72 h before the analysis. The extent of apoptosis was measured by incorporation of FITC dUTP in the presence of TdT enzyme to detect DNA fragmentation. Both compounds had negligible effect on the extent of apoptosis at the higher concentration used (Table 1 ). In addition, the expression of the bcl-2 family members involved in regulating apoptosis was also determined in PANC-1, Capan-2 and P3-HPAC cells following treatment with RGZ or PGZ. After 24-h incubation with TZD, no change in the expression of the inducers of apoptosis, bax or bak, or inhibitors of apoptosis such as bcl-2 and its close homologue bcl-xL was detected ( Figure 4 ). These results suggest that pancreatic tumor cells are relatively resistant to apoptosis induced by TZD. for 24 h. Cells were then harvested, and whole-cell protein extracts were fractionated by sodium dodecyl sulfate-polyacrylamide electrophoresis and transferred to nitrocellulose paper as described in Methods. Different proteins were detected by incubating the filter with specific antibodies.
TZD promoted differentiation and reversal of the transformed phenotype in PPAR-expressing cells
In the PPAR-expressing cell line, PANC-1, 72-h incubation with RGZ resulted in morphological changes with more abundant, flattened cytoplasm, and increased cytoplasmic/ nuclear ratio, as is consistent with a more mature phenotype ( Figure 5B ). To determine whether morphological changes and growth arrest were accompanied by differentiation, analysis of markers of the differentiated state was performed. Treatment with 20 mol/L of RGZ resulted in a timedependent increased expression of ductal specific markers such as carbonic anhydrase II (CA II) [5] and cytokeratin 7 [35] as well as "general" differentiation markers such as the cell cycle inhibitors p21 and p27 ( Figure 5A ). Expression of 
DISCUSSION
Here we studied the effects of two TZD, pioglitazone (PGZ) and rosiglitazone (RGZ), on pancreatic cancer cell growth, and we characterized the relationship between PPAR expression and their anticancer properties. The two TZD similarly induced a strong inhibition of anchorageindependent growth on PPAR-expressing cell lines but they had no effect on colony formation of the PPAR-deficient cells, HPAC ( Figure 1B) . The role of PPAR in the antiproliferative effect of TZD in pancreatic cancer cells was confirmed by overexpression of the receptor in HPAC cells. Expression of PPAR in HPAC cells, obtained by transducing retrovirus, restored the growth inhibitory effect of TZD in parallel with a significant induction of PPRE reporter activity ( Figure 2B, C) . We therefore, conclude that PPAR expression determines TZD sensitivity in pancreatic carcinoma cells. Confirming our result, the reduction of DNA accumulation by RGZ in glioma cells is strictly dependent on PPAR expression [36] . In addition RGZ exclusively inhibits anchorage-independent growth in human colorectal cancer cells that express a transcriptionally active PPAR [18] . This data is, however, partially in contrast with the observation that the anticancer effects of TZD are independent of PPAR and mediated by inhibition of translation initiation [37] . In fact, in PPAR ES cells troglitazone induced cell cycle arrest by partial depletion of intracellular Ca 2+ stores, activation of the double-stranded RNAdependent protein kinase (PKR), and phosphorylation of the eukaryotic initiation factor 2 (eIF2). Furthermore, Abe et al have indicated that troglitazone suppressed cell growth and histamine secretion by a PPAR-independent mechanism in the human basophilic leukemia cell line KU812 [38] . A possible explanation of this controversy may be due to the different chemical structure of the various members of TZD family. Only troglitazone, for instance, has the chroman structure of vitamin E, suggesting that this TZD could regulate signal pathways by mimicking the effects of vitamin E and independently of PPAR transcriptional activation [39] . To define the mechanisms by which TZD inhibit the growth of pancreatic carcinoma cells, we analyzed the cell cycle profile of cells treated with RGZ and PGZ. Both TZD increased the population of cells in G 1 /G 0 phase and reduced the population of cells in S phase in PPAR-expressing cells (Figure 3) . These results support recent observations in other growing cells, such as colon cancer cells and myeloid leukemia cells, showing that PPAR activation induce G 1 cell cycle arrest [18, 40] . These cycle alterations were achieved at TZD concentrations that repressed pancreatic cell growth, indicating that cell-cycle arrest is one of the primary mechanisms responsible for the anti-proliferative action of TZD in pancreatic cancer cell in vitro.
Apoptosis and cell differentiation are tightly linked to cell cycle control mechanisms, particularly those that regulate the transit through G 1 phase [41, 42] . Thus, the induction of G 1 arrest by TZD-activation of PPAR may be the precipitating molecular events for subsequent cell differentiation or death. We did not find any pro-apoptotic effects in PPAR-expressing and non-expressing cells after TZD treatment at the highest concentration used (Table 1 and Figure 4) , whereas a significant time-dependent induction of both general and ductal-specific differentiation markers was observed after TZD treatment in PANC-1 cells and in the PPAR overexpressing clone, P3-HPAC. This suggests that the in vitro anti-proliferative effects of TZD in pancreatic tumor cells are not primarily mediated by the induction of apoptotic cell death. Our findings are consistent with the apoptotic-resistant phenotype characteristic of pancreatic tumor cells that are resistant to undergoing apoptosis induced by chemotherapeutic agents, activation of surface receptors such as CD 95 or by serum and growth factor withdrawal [43, 44] . Similarly to TZD, non-steroidal anti-inflammatory drugs (NSAID) such as indomethacin and sulindac inhibit pancreatic cell growth by cell-cycle arrest without apoptosis via a COX 2 -independent mechanism [45] . Interestingly, it has been shown that NSAID are PPAR activators and their growth-inhibitory effect in pancreatic cells could be mediated, at least in part, by this receptor [46] . Furthermore, Wick et al, have recently demonstrated that PPAR is one of the molecular targets of NSAID mediating COX-independent inhibition of lung cancer cell growth [47] . In contrast, the natural PPAR ligand, 15d-PGJ 2 , induced substantial apoptosis in pancreatic cancer cells [48] . These discrepancies could be explained assuming that the effect of 15d-PGJ 2 may be partially PPAR-independent. Indeed, cyclopentenone prostaglandins have been shown to induce apoptotic cell death of human hepatic myofibroblasts, which do not express PPAR, by a mechanism involving the production of reactive oxygen species [49] . Furthermore, specific inhibition of PPAR does not prevent 15d-PGJ 2 -induced apoptosis in breast cancer cells, suggesting that this ecosanoid requires mechanisms others than activation of PPAR to induce apoptosis [50] . Although inhibition of cloning efficiency is generally considered the hallmark of differentiation, we investigated additional characteristics that would point towards a more differentiated phenotype of ductal carcinoma cells. Whereas much is known about PPAR and its role in adipocytic differentiation [11] , in part because of the identification of well-established markers of the terminally differentiated adipocyte [12] , the pancreatic ductal epithelium represents a more complex and challenging system. We found that TZD treatment induced the expression of differentiated ductal cells markers such as CK-7 [35] and CAII [5] in parallel with a significant up-regulation of the cell cycle inhibitors p21 and p27 in Panc-1 cells ( Figure 5A) . By light microscopy, we observed elongation and flattening of cells with extending cellular process after TZD treatment ( Figure 5B ). These morphological changes are strikingly similar to the ones observed after butyrate and retinoid induced differentiation in the same cell lines [5, 51] and represented a more differentiated and less malignant state. In agreement with the negligible effect of TZD on growth of PPAR non-expressing cells, these drugs have no effect on the expression of CAII and p21 in HPAC cells ( Figure 6A ). Ectopic expression of PPAR completely restored the ability of TZD to induce ductal differentiation in HPAC cells, suggesting that the expression and activation of PPAR pathway is a key step in pancreaticspecific differentiation ( Figure 6B ). Chang et al, have recently reported growth inhibition and increased expression of markers of bronchoalveolar progenitor cells in non-small cell lung cancer after treatment with PPAR agonists [52] . Similarly to our results, they did not document either lipid accumulation or adipocyte-specific gene expression, thus excluding adipocytic transdifferentiation of these cell lines. The signaling events evoked by PPAR activation in epithelial cancer cells remain unclear. The ability of TZD to establish various lineage-specific differentiated states that differ according to the cellular type would suggest that the PPAR pathway functions early in the induction of differentiation, before lineage-specific events occur.
Overall, our study demonstrates that TZD inhibits growth of pancreatic cancer cells via a PPAR-dependent induction of ductal differentiation. Given the favorable toxicity profile of these drugs and the limited treatment options that are currently available for patients with pancreatic malignancies, TZD might be a new effective approach to complement conventional chemotherapeutic regimens for pancreatic cancer therapy.
